ESMO Congress 2025 – Berlin
This week saw Frontier’s Dr Martin Burow and Dr Chris Lee at Breast Cancer 2025 in Berlin, one of the most influential global meetings dedicated to innovation and clinical progress in breast cancer research and treatment.
“With 33,000 participants, this is a major opportunity to connect with researchers and clinicians on the latest thinking. There is so much going on – it’s overwhelming – a fertile ground for new collaboration.”
Our participation at ESMO marks a key milestone in strengthening international collaboration and advancing our Sentinel qCTC system, as we continue to build a strong clinical and research network across Asia and Europe. In particular, the conference presents a valuable opportunity to:
- Engage with a wide network of clinicians from the Philippines, expanding our regional connections and exploring potential integration of Sentinel qCTC into ongoing and future breast cancer research initiatives across Southeast Asia.
- Reconnect with Japanese research partners following our productive meetings earlier this year in Japan, deepening dialogue around joint studies, CTC technology validation, and translational applications.
- Identify new collaborative pathways with European investigators, fostering partnerships that align with Frontiers’ vision of precision oncology through liquid biopsy innovation.
SCIENTIFIC AND STRATEGIC FOCUS
The ESMO Breast Cancer Congress provides a comprehensive update on the rapidly evolving field of breast cancer care—covering diagnostics, molecular biomarkers, targeted therapies, and clinical management. For the Frontier team, participation will deliver insights of immense strategic value to the ongoing development and deployment of the Sentinel qCTC system, specifically through:
- Advancing knowledge in breast cancer diagnostics and biomarkers, directly informing how CTC detection and profiling can enhance personalized treatment decisions.
- Understanding new developments in antibody-drug conjugates (ADCs) and how these emerging therapeutic classes could be monitored via CTC phenotyping and molecular characterisation.
- Gaining a deeper grasp of subtype-specific strategies—for Luminal, HER2-positive, HER2-low, and triple-negative breast cancers—where real-time CTC tracking can be pivotal in assessing therapeutic response and disease progression.
- Exploring special considerations across diverse patient subgroups, supporting Sentinel qCTC’s adaptability to a range of clinical and biological contexts.
By connecting with world-leading clinicians and researchers, Frontier continues to advance its mission: transforming precision oncology through accessible, high-performance CTC technology that empowers clinicians to make data-driven, patient-specific decisions.
